Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
The MHRA approved REDEMPLO (plozasiran) for adults with familial chylomicronaemia syndrome who have not responded adequately to diet and conventional triglyceride-lowering therapies. The treatment is also available on the NHS in England and Wales following positive guidance.
Arrowhead said NICE recommended NHS funding for REDEMPLO (plozasiran) for adults with genetically confirmed familial chylomicronemia syndrome in England and Wales, following UK marketing authorisation.